Risultati per: Nuovi farmaci promettenti contro l’Alzheimer

L’inizio tardivo della fase Rem è associato a un maggior rischio di ammalarsi

Objective
The aim of the present study was to explore the experiences and viewpoints of professional family caregivers in the management of behavioural and psychological symptoms of dementia (BPSDs) to identify the ecopsychosocial strategies applied by them.

Design
Qualitative study.

Setting
Kerman, Iran.

Participants
Stories were collected from 40 professional family caregivers of dementia patients.

Measurement
The guidelines of the National Consensus Project (NCP) of the USA served as the conceptual framework for the deductive thematic analysis of our qualitative data. A schematic of the entire process was performed in five steps.

Results
30 stories relevant to the aim of this study were included in the analysis from April to June 2021. A majority of the stories were written by female caregivers. We identified 19 ecopsychosocial interventions, which covered the NCP dimensions except ‘Care of the patient nearing the end of life’. More than half of these interventions were classified into psychological/psychiatric and physical aspects of care (57.8%). In addition to the care/support provided by special care units or home care, some caregivers believe that support from the government, various care organisations, social media and even other family members/friends is necessary to better manage BPSDs.

Conclusion
Despite limitations, such as having a small sample size and analysing only one story from each caregiver, our results indicate that dementia caregivers need more educational and cultural support in their ecopsychosocial strategies. Government involvement would yield more positive outcomes in managing BPSDs.

Studio pubblicato nella rivista Nature Communications

Esperti, ‘da depressione ad Alzheimer si studiano nuovi usi”

Studio guidato dalle Molinette di Torino. Ruolo rare mutazioni

Rallenta la ricerca sui farmaci in Italia che con le sperimentazioni cliniche – passate nel 2023 a 611 dalle 663 dell’anno prima (-7,8%) – muove ogni anno 700-800 milioni di…

Nistico’, sistema italiano tiene ma -7,8% trial,1 su 3 oncologico

Fujifilm Diosynth Biotechnologies costruirà i nuovi impianti nel sito danese di Hillerød in grado di produrre una maxi coltura di cellule per le terapie

Rischio più alto per donne; attesi 1 milione di nuovi casi annui

Anche del declino cognitivo lieve

Multilingue, chiarirà dubbi e timori assunzione medicinali

Perché risvegliano virus latenti dannosi

Protagoniste le cellule immunitarie del cervello